Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials

Abstract

NOAH-AFNET 6 was partially funded by BMBF (German Ministry of Education and Research, Berlin, Germany) through the DZHK (German Centre for Cardiovascular Research, Berlin, Germany, grant number FKZ 81X2800182) and by Daiichi Sankyo Europe. Further support for analysis was provided by European Union CATCH ME (grant agreement no. 633196) to P.K. and U.S. and AFNET; AFFECT EU (grant agreement 847770) to P.K.; MAESTRIA (grant agreement 965286) to A.G., P.K., U.S. and AFNET; British Heart Foundation (AA/18/2/34218); German Research Foundation (Ki 509167694); DZHK (grant numbers 81Z0710116 and 81Z0710110), Leducq Foundation, and the Dutch Heart Foundation (EmbRACE, grant number 01-002-2022-0118). The ARTESiA study was funded by grants from the Canadian Institutes of HealthResearch (201610PTJ-378238), the Bristol Myers Squibb–Pfizer Alliance, the Heart and Stroke Foundation of Canada, the Canadian Stroke Prevention Intervention Network, Hamilton Health Sciences, the Accelerating Clinical Trials Network, the Population Health Research Institute, and Medtronic. The sponsors had no role in data analysis, interpretation, or publication. R.B.S. received funding from Union’s Horizon 2020 research and innovation programme under the grant agreement no. 648131, from the European Union’s Horizon 2020 research and innovation programme under the grant agreement no. 847770 (AFFECT-EU), from the European Union’s Horizon Europe research and innovation programme under the grant agreement ID: 101095480 and German Centre for Cardiovascular Research (DZHK e.V.) (81Z1710103 and 81Z0710114); German Ministry of Research and Education (BMBF 01ZX1408A) and ERACoSysMed3 (031L0239); and Wolfgang Seefried project funding German Heart Foundation.